Denosumab

First-line therapeutic drugs for osteoporosis (0PJ, New selection for patients with solid tumor bone metastasis

Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology.

Indications:

Treatment of postmenopausal women with osteoporosis at high risk of fractures [60mg (1.0mL)]. 

Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [120mg (1.7mL)].

STRENGTH:

60mg (1.0mL)

120mg (1.7mL)